Xeris Biopharma (XERS) News Today $5.63 -0.08 (-1.40%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$5.73 +0.10 (+1.78%) As of 03/27/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27 at 11:39 AM | msn.comXeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - Time to Buy?March 25 at 12:26 PM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 106.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,332 shares ofMarch 23, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 SharesXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 22, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's WhyXeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's What HappenedMarch 22, 2025 | marketbeat.com12 Best Stocks to Invest in for a Stock Market GameMarch 20, 2025 | insidermonkey.comXeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market GameMarch 19, 2025 | insidermonkey.comCalculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)March 18, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Sets New 12-Month High - Still a Buy?Xeris Biopharma (NASDAQ:XERS) Hits New 52-Week High - Here's What HappenedMarch 18, 2025 | marketbeat.comFDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aidMarch 17, 2025 | markets.businessinsider.comXeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic AidMarch 17, 2025 | finance.yahoo.comGlobeflex Capital L P Takes $424,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Globeflex Capital L P purchased a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 125,210 shares of the company's stockMarch 17, 2025 | marketbeat.comXeris Biopharma: Low Risk, Low Excitement Solid Revenue GeneratorMarch 16, 2025 | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - Here's What HappenedXeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume - Still a Buy?March 15, 2025 | marketbeat.comXeris Biopharma Holdings Share Price (XERS.US)March 12, 2025 | lse.co.ukXeris Biopharma (NASDAQ:XERS) Sets New 1-Year High - Should You Buy?Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - What's Next?March 12, 2025 | marketbeat.comXeris Biopharma - Possibly the best Pharma StockMarch 11, 2025 | msn.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendationMarch 11, 2025 | marketbeat.comXeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025March 11, 2025 | markets.businessinsider.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comXeris Biopharma (NASDAQ:XERS) Price Target Raised to $6.00Leerink Partners upped their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday.March 10, 2025 | marketbeat.comCraig Hallum Raises Xeris Biopharma (NASDAQ:XERS) Price Target to $6.50Craig Hallum boosted their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a report on Friday.March 10, 2025 | marketbeat.comEssex Investment Management Co. LLC Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Essex Investment Management Co. LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 474,955 shares of the company's stock, valued atMarch 10, 2025 | marketbeat.comAnalysts Issue Forecasts for Xeris Biopharma Q1 EarningsXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Xeris Biopharma in a research report issued on Friday, March 7th. HC Wainwright analyst O. Livnat forecasts that the company will post earnings of ($0.08) per share for theMarch 10, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Price Up 4.7% - Here's What HappenedXeris Biopharma (NASDAQ:XERS) Stock Price Up 4.7% - Here's What HappenedMarch 8, 2025 | marketbeat.comPiper Sandler Reiterates Neutral Rating for Xeris Biopharma (NASDAQ:XERS)Piper Sandler reiterated a "neutral" rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday.March 8, 2025 | marketbeat.comXeris Biopharma price target raised to $6.50 from $5 at Craig-HallumMarch 8, 2025 | markets.businessinsider.comXeris Biopharma (NASDAQ:XERS) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday.March 8, 2025 | marketbeat.comXeris Biopharma price target raised to $6 from $5 at LeerinkMarch 8, 2025 | markets.businessinsider.comXeris Biopharma (NASDAQ:XERS) Hits New 1-Year High After Better-Than-Expected EarningsXeris Biopharma (NASDAQ:XERS) Sets New 1-Year High on Strong EarningsMarch 7, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Announces Quarterly Earnings ResultsXeris Biopharma (NASDAQ:XERS - Get Free Report) issued its earnings results on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.05.March 7, 2025 | marketbeat.comXeris Biopharma Shares Rise on Expectation of Significant Full-Year Revenue GrowthMarch 7, 2025 | marketwatch.comXeris Biopharma price target raised to $8 from $6.60 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comXeris Biopharma price target raised to $4 from $3 at Piper SandlerMarch 7, 2025 | markets.businessinsider.comXeris Biopharma reports Q4 EPS (3c), consensus (2c)March 6, 2025 | markets.businessinsider.comXeris Biopharma sees FY25 revenue $255M-$275M, consensus $239.77MMarch 6, 2025 | markets.businessinsider.comXeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 GuidanceMarch 6, 2025 | businesswire.comXeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comCraig-Hallum Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)March 3, 2025 | markets.businessinsider.comXeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025February 27, 2025 | businesswire.comXeris Biopharma (XERS) Expected to Announce Earnings on WednesdayXeris Biopharma (NASDAQ:XERS) will be releasing earnings before the market opens on Wednesday, March 5, Financial Modeling Prep reports.February 26, 2025 | marketbeat.comXeris Biopharma CEO Ken Johnson to retire, Anh Nguyen to succeedFebruary 25, 2025 | markets.businessinsider.comXeris Appoints Anh Nguyen, MD, MBA as Chief Medical OfficerFebruary 24, 2025 | finance.yahoo.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutionsFebruary 20, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - Still a Buy?Xeris Biopharma (NASDAQ:XERS) Hits New 1-Year High - Still a Buy?February 19, 2025 | marketbeat.comLegato Capital Management LLC Makes New $482,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Legato Capital Management LLC purchased a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 142,164 sharesFebruary 15, 2025 | marketbeat.comThe American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and AwarenessJanuary 21, 2025 | prnewswire.comXeris Expects to Exceed Full-Year 2024 Financial GuidanceJanuary 10, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Stock Price Up 5.7% - Here's WhyXeris Biopharma (NASDAQ:XERS) Trading 5.7% Higher - Should You Buy?January 10, 2025 | marketbeat.comBarclays PLC Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Barclays PLC boosted its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 87.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 324,472 shares of the company's stock afterDecember 31, 2024 | marketbeat.com Remove Ads Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Media Mentions By Week XERS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XERS News Sentiment▼0.530.78▲Average Medical News Sentiment XERS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XERS Articles This Week▼72▲XERS Articles Average Week Remove Ads Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News ALVO News RYTM News MRUS News CRNX News IMVT News VKTX News PTGX News SRRK News BHVN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XERS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XERS Stock Free XERS Stock Alerts